Using a Russian 287-FZ personal foundation in pharmaceuticals brings sector-specific procedural steps. What HNWI advisers need to know. Make an enquiry.
A pharmaceutical business owner structuring Russian assets through a personal foundation under Federal Law No. 287-FZ faces procedural requirements that go beyond the standard registration pathway. The intersection of foundation law and pharmaceutical licensing in Russia generates a specific sequence of steps that, if addressed out of order, can interrupt the continuity of licensed activity — with material consequences for the underlying business. This note sets out the key procedural points for advisers acting for owners of pharmaceutical businesses who are considering or are already in the process of establishing a personal foundation in Russia.
Federal Law No. 287-FZ, in force since 2022, introduced the personal foundation (lichnyi fond) as a distinct organisational form under Russian civil law. The personal foundation holds assets transferred by the founder during his or her lifetime and manages them in accordance with conditions set out in the foundation's charter and conditions of management — documents approved at the point of establishment and binding on the management body going forward.
The standard procedural sequence under Russian law runs broadly as follows: the founder executes the foundation charter, which sets out management conditions including the distribution of assets and income among beneficiaries; the foundation is then registered with the Federal Tax Service as a legal entity; assets are transferred into the foundation's ownership by civil-law instruments (sale, donation, contribution in kind, or otherwise); and the management body assumes operational control of those assets.
For founders whose asset base includes shares or participatory interests in pharmaceutical companies — or direct ownership of pharmaceutical facilities, inventory, or intellectual property related to medicinal products — this sequence requires adjustment. Under Russian law, a pharmaceutical licence attaches to the licensed legal entity, not to its shareholder. A change in the ownership structure of that entity, including a transfer of shares to a personal foundation, does not of itself affect the licence; the licensed company continues to operate under its existing authorisation. This is the general position, and advisers should not conflate it with the separate question of whether regulatory notification is required.
Note: In practice, certain categories of pharmaceutical activity require the licensor — the Ministry of Health or a regional authority, depending on the activity type — to be notified when there is a material change in the composition of participants of the licensed legal entity. The threshold for "material change" is interpreted variously across licensing authorities and has not been uniformly resolved in published regulatory guidance. Advisers should verify the applicable notification requirement directly with the relevant licensor before or promptly after completing the transfer of shares to the foundation. Failure to notify where required may trigger administrative consequences for the licensed entity, separate from any effect on the foundation itself.
A second procedural consideration concerns the valuation of pharmaceutical assets transferred to the foundation. Russian law requires that the value of the property forming the initial endowment of a personal foundation meet a statutory minimum threshold. Where the assets to be transferred include participatory interests in pharmaceutical companies, an independent valuation is required. In the pharmaceutical context, the value of such interests is frequently bound up with the company's licences, its regulatory history, and its drug-registration portfolio — intangible elements that standard asset-valuation methodologies may not capture with precision. Advisers should ensure that the valuation instruction specifies pharmaceutical-sector expertise and addresses the regulatory asset base expressly.
The procedural sequence for a pharmaceutical business owner typically involves parallel workstreams rather than a linear progression. Foundation registration proceeds through the Federal Tax Service on the standard timeline for legal entity registration under Russian law. Asset transfer documentation is prepared concurrently, but the effective transfer of shares or interests in pharmaceutical companies is typically deferred until the licensing notification question has been resolved and, where required, confirmation from the licensor obtained.
A further practical point concerns the foundation's management conditions. The conditions of management document — a founding instrument unique to Russian personal foundation law, with no precise analogue in common-law trust practice — defines the powers of the management body, the circumstances in which the founder may reclaim assets, and the order of distribution among beneficiaries. For a founder whose principal asset is a pharmaceutical business, the conditions of management should address at minimum: the management body's authority (or its limits) in relation to decisions that affect the licensed entity's regulatory standing; the procedure for asset reversion in the event that a licensing authority takes adverse action against the licensed entity; and the treatment of income derived from pharmaceutical activity for distribution purposes.
These drafting choices have procedural consequences. A foundation whose conditions of management are silent on regulatory contingencies may require amendment — itself a formal procedure under Russian law — if a licensing issue arises after establishment. Amendment of foundation documents is subject to the founder's reserved powers as defined in the charter and is not available to beneficiaries or the management body acting alone. Early-stage drafting precision accordingly reduces procedural friction over the foundation's operating life.
Finally, advisers should be aware that personal foundations under 287-FZ are subject to Russian tax residence rules on their worldwide income from the point of registration. For a founder whose pharmaceutical holdings generate income streams across multiple jurisdictions — as is increasingly common in the EAEU context — the tax residence implications of the foundation's registration date should be modelled before, not after, the registration application is submitted.
Structuring decisions of this nature benefit from early-stage analysis, before formal proceedings create constraints on available options. For advisers acting for pharmaceutical business owners approaching the personal foundation route, the following points warrant resolution at the outset: the scope of assets to be transferred and whether any of those assets trigger licensing notification obligations; the valuation methodology for pharmaceutical interests and its adequacy for the statutory endowment threshold; the drafting of the conditions of management, with particular attention to regulatory contingencies; and the tax residence modelling for the foundation and the founder across all relevant jurisdictions.
To discuss the structuring of a personal foundation under Russian law for a pharmaceutical business owner — make an enquiry: info@vetrovpartners.com |
This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.
Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.
Make an enquiry